source
- Servier’s $1.55 billion Becker muscular dystrophy drug fails pivotal Phase 3 trialServier announced that its experimental drug for Becker muscular dystrophy did not meet its primary endpoint in a Phase 3 trial called GRAND CANYON. The drug, sevasemten, was acquired from Edgewis…
- Neurocrine launches new safety study after another death linked to Prader-Willi drug VykatNeurocrine Biosciences announced it will start a new study to evaluate dosing and safety of its rare disease drug Vykat in patients with Prader-Willi syndrome who have complex health issues. The m…